The University of Nebraska Medical Center and Nebraska Medicine will be part of Liberia – U.S. clinical research partnership to test Ebola treatments that includes an experimental drug. The drug, ZMapp has been used to treat several patients with Ebola but not during a clinical trial to determine the exact benefits.
Dr. Andre Kalil is a professor at UNMC and an infectious disease physician at Nebraska Medicine and was involved in designing the study.
Dr. Kalil says, “We will find out what is working and what is not working while the clinical trial is ongoing and adapt the study on patients’ clinical response. The idea is to discover and offer the safest and best therapies in the shortest period of time.”
UNMC/Nebraska Medicine expects to receive approval of the study in a few weeks. Health officials plan to enroll adults and children diagnosed with Ebola in Liberia, health care workers infected and have returned to the U.S for treatment and those in the U.S who were infected through secondary transmission.
Several other universities and medical centers around the country are taking part.